Title: Incidence rate estimation, periodic testing and the limitations of the mid-point imputation approach
Authors: Vandormael A, Dobra A, Barnighausen T, de Oliveira T, Tanser F.
Journal: International Journal of Epidemiology,:doi.org/10.1093/ije/dyx134 (2017)
Background: It is common to use the mid-point between the latest-negative and earliest-positive test dates as the date of the infection event. However, the accuracy of the mid-point method has yet to be systematically quantified for incidence studies once participants start to miss their scheduled test dates.
Methods: We used a simulation-based approach to generate an infectious disease epidemic for an incidence cohort with a high (80-100%), moderate (60-79.9%), low (40-59.9%) and poor (30-39.9%) testing rate. Next, we imputed a mid-point and random-point value between the participant's latest-negative and earliest-positive test dates. We then compared the incidence rate derived from these imputed values with the true incidence rate generated from the simulation model.
Results: The mid-point incidence rate estimates erroneously declined towards the end of the observation period once the testing rate dropped below 80%. This decline was in error of approximately 9%, 27% and 41% for a moderate, low and poor testing rate, respectively. The random-point method did not introduce any systematic bias in the incidence rate estimate, even for testing rates as low as 30%.
Conclusions: The mid-point assumption of the infection date is unjustified and should not be used to calculate the incidence rate once participants start to miss the scheduled test dates. Under these conditions, we show an artefactual decline in the incidence rate towards the end of the observation period. Alternatively, the single random-point method is straightforward to implement and produces estimates very close to the true incidence rate.
Citation: Vandormael A, Dobra A, Barnighausen T, de Oliveira T, Tanser F. Incidence rate estimation, periodic testing and the limitations of the mid-point imputation approach International Journal of Epidemiology,:doi.org/10.1093/ije/dyx134 (2017).
Prevalence of drug-resistant HIV reaches 'alarming levels' in ArubaHealio News - 2017-03-17
The prevalence of resistance to nonnucleoside reverse transcriptase inhibitors among HIV-infected individuals has increased to 'alarming levels' in Aruba, reaching 45% in 2015, see our recent publication at CID.
Perspective: Extreme high-level of drug resistance in Aruba: We need ITI-based regimens available globally now!Healio News: IAS Perspective - 2017-03-17
Perspective by Carlos del Rio, MD Professor of medicine, division of infectious diseases, Emory University School of Medicine on our recent CID manuscript on high-level transmitted resistance epidemic in Aruba.
KRISP has been created by the coordinated effort of the University of KwaZulu-Natal (UKZN), the Technology Innovation Agency (TIA) and the South African Medical Research Countil (SAMRC).